Failure to publish and selective reporting are recognized problems in the biomedical literature, but their extent in the field of diagnostic testing is unknown. We aimed to identify nonpublication and discrepancies between registered records and publications among registered test accuracy studies.
In recent years, failure to publish studies and selective reporting of research findings, each related to the strength and direction of outcomes (1, 2 ) , have been demonstrated several times in the biomedical literature (3, 4 ) . Studies with favorable results were shown to be more likely to be published than studies with negative or disappointing ones (3, 5 ) . This is regrettable for several reasons. The nonreporting of research results may lead to unnecessary duplication of research efforts, wasting time and money. Furthermore, the absence of information in the public domain can affect the evidence base on which clinical decisions are made (6 ) . Systematic reviews, which have now achieved a fundamental role in modern evidence-based health care, are especially sensitive to the selective absence of study findings, since unpublished research results are difficult to find and include. This may lead to skewed syntheses of the evidence, biased estimates of the effectiveness of healthcare interventions, and eventually, unnecessary exposure of patients to potentially ineffective or harmful interventions (7 ) .
In 2005 the International Committee of Medical Journal Editors (ICMJE 3 ) decided to require researchers to register essential information about the design of randomized controlled trials, before initiation, in a publicly accessible register (8 ) , such as ClinicalTrials. gov (9 ) . Study registration is seen as an important solution for recognizing reporting biases since, in principle, nonpublication and selective reporting can easily be identified.
So far, most demonstrations of failure to publish and selective reporting have targeted randomized clinical trials (10 ) . The extent to which similar mecha-nisms are active in research estimating the accuracy of diagnostic and prognostic medical tests and markers is largely unknown (11) (12) (13) . Although registration of test accuracy studies is currently not required by the ICMJE, increasing numbers of these studies seem to be registered. The main objectives of our study were to identify nonpublication and discrepancies between registered records and corresponding publications in a cohort of test accuracy studies registered in ClinicalTrials.gov. We also explored associations between study characteristics and nonpublication.
Methods

CREATION OF CLINICALTRIALS.GOV COHORT
A cohort of test accuracy studies registered in ClinicalTrials.gov was identified. Details on the registry search are provided in Supplemental Methods 1, which accompanies the online version of this article at http:// www.clinchem.org/content/vol60/issue4. The search was limited to studies that were first received between January 1, 2006, and December 31, 2010.
Studies were included if their objective was to evaluate the accuracy of a medical test (the index test) in correctly classifying human subjects as having the target condition, evaluated against a clinical reference standard. The results of such studies are typically reported in terms of sensitivity and specificity, predictive values, or area under the ROC curve. Because outcomes are sometimes vaguely registered, or not registered at all, we also included studies that did not explicitly mention any accuracy measure but for which one could be calculated on the basis of the information included in the registry. Studies primarily evaluating the analytical or technical performance of a test were excluded.
We selected studies for which the study completion date was set before October 2011, thereby allowing at least 18 months between intended completion and publication. Also, studies with an unknown (instead of completed) study status in ClinicalTrials.gov were included if they met this criterion. The status of these studies is characterized as unknown by the registry if it has not been confirmed within the past 2 years. If no completion date was provided, the primary completion date was used (n ϭ 18). If neither date was reported, a study was included only if the study status had been updated to completed before October 2011, as recorded in the history of changes option in ClinicalTrials.gov (n ϭ 8). In addition, studies were excluded whenever their status in the registered record indicated that the study had been suspended, terminated, or withdrawn. One author (D.A. Korevaar) scanned the search results to identify studies meeting the inclusion criteria. If there was any doubt that a study met the inclusion criteria, the case was discussed with a second author (P.M.M. Bossuyt).
IDENTIFYING PUBLICATIONS
In April and May 2013, one author (D.A. Korevaar) undertook the following steps to identify matching publications in peer-reviewed biomedical journals. First, the publications field in ClinicalTrials.gov was examined. If no reference of an article was reported, MEDLINE (through PubMed) and EMBASE were searched by use of the trial registration number, registry title, name of the principal investigator or other contact person, and index test and condition studied (including synonyms). When no publication was identified, Web of Science was searched by combining the search strategy with the institution, city, and country where a study was performed.
In May 2013, a second author (E.A. Ochodo) repeated the search for studies for which no publication had been identified. If still no publication was found, one author (D.A. Korevaar) tried to contact the principal investigator of the study by email, by use of contact information provided in the registry, or, if this was outdated or not available, by searching for corresponding e-mail addresses through previously published studies or Google. E-mails were sent in June 2013. Contact attempts were limited to 3 emails, each a week apart. If no answer was received, a study was considered as unpublished. If there was any doubt that a study identified through our searches matched with the registered record, the investigators were also contacted for confirmation. If no response was received, the case was again discussed with another author (P.M.M. Bossuyt). If studies had other objectives besides investigating the accuracy of a test, the study was considered as published only if the accuracy part was reported in a publication.
DATA EXTRACTION
One author (D.A. Korevaar) performed the data collection. Included studies were categorized as registered before initiation (defined as registered before or in the same month as the registered start date), after completion (defined as registered in the same month as or after the registered completion date), or in between (defined as registered after the month of the registered start date but before the month of the registered completion date). We also classified studies as diagnostic accuracy studies, prognostic accuracy studies, imaging studies, laboratory technique studies, or other.
The main funding sources of a study are categorized in ClinicalTrials.gov into NIH, other US federal agency, industry, or others (including individuals, universities, nonprofit organizations). We further categorized NIH and US federal into government. We also extracted the anticipated number of enrolled patients from the registry. If this number had changed during the course of the study, we took the first one recorded. We classified the country in which the study was performed as (a) US; (b) Canada, Australia, and New Zealand; (c) European Union and Switzerland; or (d) other.
IDENTIFYING DISCREPANCIES BETWEEN REGISTRIES AND PUBLICATIONS
One author (D.A. Korevaar) compared each registered record with the final publication regarding inclusion criteria, index tests and positivity thresholds, and primary outcomes and secondary accuracy outcomes. Studies registered after completion were excluded from this analysis, since they make a formal assessment of selective reporting impossible. Studies were subdivided into those with clear discrepancies between the registry and publication, those where an objective comparison was not possible due to vaguely, retrospectively, or unregistered information, and those with no or minor discrepancies. We considered discrepancies as minor when all the registered accuracy measures were reported in the publication, even if others were added, and when the registered accuracy outcome was only partially reported (e.g., only sensitivity and specificity were reported, whereas likelihood ratios were not). If a reason for deviating from the registered information was provided in the publication, it was not considered as a discrepancy. The classification of each study was confirmed by a second author (L. Hooft), with disagreements resolved by consensus.
STATISTICAL ANALYSIS
Descriptive statistics are reported as frequencies and percentages, and as medians with interquartile ranges (IQRs) for skewed continuous variables. We used 2 tests to examine associations between study characteristics and publication status, allowing at least 30 months between intended study completion and publication. We also analyzed these data when excluding studies that registered after completion or with an unknown (instead of completed) study status, since these studies were highly likely to respectively over-and underestimate publication rates.
We performed Kaplan-Meier survival analysis to estimate the time to publication, defined as the time (in months) between study completion (as provided in the registry) and publication (defined as the date when the article was first published in full online or appeared in print, whichever came first). Only studies that registered a completion date were included in this analysis. Publication times for unpublished studies were considered censored on March 2013, the month before we started our searches. Studies published before the completion date (n ϭ 23) were considered as published at time 0 in these analyses. Data were analyzed by use of SPSS version 20.0.
Results
INCLUDED STUDIES
The search in ClinicalTrials.gov identified 1129 studies, of which 711 had to be excluded (Fig. 1) . In the excluded studies, 63 had been withdrawn (n ϭ 17), terminated (n ϭ 36), or suspended (n ϭ 10). Of these, 54 studies provided in total 56 reasons for not completing the study. Reported reasons referred to recruitment problems (n ϭ 17); sponsor decisions, financial problems, or lack of time or manpower (n ϭ 15); design problems (n ϭ 5); a principal investigator who had moved (n ϭ 4); institutional review board (IRB) decisions (n ϭ 2); a product being withdrawn from the market (n ϭ 2); or other reasons (n ϭ 11). Characteristics of the 418 included studies are summarized in Table 1 . In short, almost a quarter of the studies had been registered after completion, and a quarter of the studies had not changed their status to completed, although the completion date indicated that they should have been finished. Nearly half of the studies investigated an imaging test, with very few prognostic tests. A quarter of the studies were sponsored by industry, only 4% by government. The remaining 297 studies had another type of funder, mostly universities (n ϭ 171). The great majority of the studies had been performed in the US (36%) or in the European Union and Switzerland (32%). The median study duration was 19 months (IQR 11-30), and the median anticipated sample size was 172 (IQR 80 -412).
PUBLICATION RATES
No publication could be found for 194 of the 418 included studies. The investigators of 113 of these studies (58%) confirmed that the study had not been published (Fig. 1) . Five of them indicated that the study was accepted for publication, 4 manuscripts had been rejected, and 12 had been submitted and were awaiting editorial decisions. Three studies were still ongoing, 7 had been stopped early and their results had not (yet) been published, and 1 had never started. The other responding investigators answered that the study had not (yet) been published. Of the published studies, 129 (58%) included a registration number in at least 1 article. Of these, only 65 provided the registration number in the abstract. A reference to at least 1 of the publications was provided in the registry for 80 (36%) studies. Seventy-four studies both included a registration number in the publication and provided a reference to the publication in the registry.
Of the included studies, 224 (54%) had resulted in 1 (n ϭ 184), 2 (n ϭ 18), 3 (n ϭ 14), 4 (n ϭ 4), 5 (n ϭ 3), or 7 (n ϭ 1) publications, with an estimated median time to publication of 35 months (95% CI 29.0 -41.0) in the Kaplan-Meier analysis. For published studies, the median time to publication was 18 months (95% CI 15.7-20.3). Among the 282 studies that had been completed at least 30 months before our analyses, 128 (45%) were published within 30 months after their date of completion. Studies registered after completion were more likely to be published (76%) than studies registered before initiation (42%) or studies registered between initiation and completion (51%, P Ͻ 0.001) (see online Supplemental Table 1 ). Studies for which the study status indicated that the study was completed were more often published (59%) than studies with an unknown status (36%, P Ͻ 0.001).
When we excluded studies registered after completion and studies with an unknown study status, we found that 120 of 228 studies (53%) had been published, with an estimated median time to first publication of 33 months (95% CI 23.7-42.3) (Fig. 2) . The median time to publication of published studies in this subgroup was 15 months (95% CI 12.5-17.5 months), and 66 of 149 studies (43%) that had been completed 30 months before our analyses were published within 30 months after their completion.
In studies that had registered a completion date, 49 of 67 (73%) completed before 2008, 41 of 59 (70%) completed in 2008, 48 of 90 (53%) completed in 2009, 53 of 107 (50%) completed in 2010, and 22 of 69 (32%) completed in 2011 were published (P Ͻ 0.001). When we excluded studies registered after completion and studies with an unknown study status, these rates were respectively 65% (11/17), 64% (25/39), 50% (25/50), 56% (38/68), and 38% (18/47) (P ϭ 0.119). Publication rates in subgroups defined by study characteristics, of studies with at least 30 months after intended completion and our analyses, are presented in Table 2 . Besides timing of registration (before initiation/after completion/in between) and study status (completed/unknown), the country where the study had been performed was significantly associated with study publication, but after exclusion of studies registered after completion and studies with an unknown study status, this association was no longer present. Study duration was significantly associated with publication, after exclusion of studies registered after completion and studies with an unknown study status; fewer studies lasting up to 1 year were published than studies of 1-2 years or longer. We observed no significant associations between publication rates and other study characteristics, such as type and aim of the test, primary funder, or sample size.
COMPARISON BETWEEN REGISTRIES AND PUBLICATIONS
Seventy-one published studies had been registered after completion and were excluded from our comparisons between registries and corresponding publications. Of the remaining 153 published studies, 49 (32%) showed clear discrepancies between the registry and the publication regarding the inclusion criteria, the index test and/or corresponding threshold, or the outcomes.
The inclusion criteria had changed in 19 (12%) studies. An unambiguous appraisal of discrepancies was difficult in 10 (7%) other studies, because the registered inclusion criteria were much more vague. Nine (6%) studies showed discrepancies in the index test or threshold: in 8 studies, 1 or more registered index test(s) were not reported in the publication, and in 1 study, a registered cutoff value differed from the published one. We were unable to completely exclude discrepancies in another 23 (15%) studies: information on the index test was more vague in the registry than in the publication for 8 studies, and among 19 studies that reported a predefined cutoff value in the methods section of their paper, 15 did not register this value.
A comparison of registered and published outcomes was not possible in 22 studies (14%) because no outcomes had been registered (n ϭ 6), outcomes were registered after study completion (n ϭ 4), or outcomes were registered much more vaguely (n ϭ 12). Of the remaining 131 studies, 32 (24%) showed discrepancies: a registered primary outcome was omitted (n ϭ 14), a registered primary outcome had become secondary Time from study completion to publication, excluding studies registered after completion and those with an unknown (instead of completed) study status. (n ϭ 7), a registered secondary outcome had become primary (n ϭ 6), an outcome absent in the registry had become primary (n ϭ 7), a registered secondary accuracy outcome was completely omitted in the publication (n ϭ 11), or the timing of assessment had changed (n ϭ 2). Many studies showed discrepancies that we considered as minor. Registered outcomes were often unspecific regarding the accuracy measures that would be calculated (n ϭ 43); instead, vague or general terms such as "diagnostic value" or "diagnostic accuracy" were used. Of the studies that were specific about the accuracy measures that would be calculated, 23 reported all the registered accuracy measures in the publication but added several (unregistered) others in the publication, and for 7, the registered accuracy outcome was only partially reported. Primary and secondary outcomes were often not explicitly distinguished in published papers, and in 11 publications, the registered primary outcome seemed at least equally important as the registered secondary outcome.
Discussion
We evaluated failure to publish and selective reporting in a cohort of test accuracy studies registered in ClinicalTrials.gov. Only slightly more than half of the studies that had been completed 18 months or longer before our analyses were found to be published in a peer-reviewed biomedical journal. Although publication rates increased over time, about one third of the studies completed before 2009 were still unpublished by mid-2013. Discrepancies between the registered record and publication regarding the inclusion criteria, index tests, thresholds, and/or primary outcomes or secondary accuracy outcomes appeared in one third of the published studies that had been registered before study completion. Unfortunately, an unambiguous assessment of selective reporting was not always possible due to scarce, absent, or retrospectively registered information.
We acknowledge that our study has several potential limitations. We may have missed publications, despite our efforts to identify published reports. Two authors thoroughly searched 3 databases, and responses to our email survey were satisfactory; nonpublication was confirmed for 58% of the studies for which we had not identified a publication. For our analyses we relied on information provided in the registry but this information has proven to be not always accurate. For example, the registered completion date differed sometimes from the published completion date, and several studies were published before the registered completion date. The estimated time from completion to publication may therefore be inaccurate and can be expected to be longer. We cannot generalize our results to unregistered test accuracy studies without some form of caution. The ICMJE currently does not require registration for test accuracy studies, and such registration may therefore happen selectively. However, it seems unlikely that publication rates are higher among unregistered studies. Authors who are willing to register their test accuracy study may be more aware of the negative effects of failure to publish and, consequently, be more motivated to publish results, even when unsatisfactory. Several studies registered their outcomes near the end of the study, when the direction of the results was probably already known. This may have affected our estimates of discrepancy rates between registries and publications.
Failure to publish and selective outcome reporting are widely recognized problems in the biomedical literature. Evidence from large cohorts of registered clinical trials, both randomized and nonrandomized, suggests that only between 46% and 63% get published (14 -16 ) . We found similar results among test accuracy studies: 54% of the studies completed at least 18 months before our analyses, and 59% completed at least 30 months before our analyses, were published. These numbers may be considered as optimistic, because we excluded studies that had enrolled patients but discontinued before study completion. Two recent evaluations with study designs similar to ours assessed time to publication among registered clinical trials funded by the NIH (17 ) and the National Heart, Lung, and Blood Institute (18 ) . Respectively 46% (294/635) and 57% (132/244) of the trials had been published within 30 months of completion, which is comparable to the 45% rate found in our study. Median time to publication among published studies in our analysis was 15-18 months. This seems acceptable, especially in comparison with clinical trials, where median time to publication for published studies was estimated to be around 23 months (17 ) . In other research fields, industry-funded trials have been associated with lower publication rates (14, 15 ) . Besides study duration, we did not identify study characteristics significantly associated with publication.
In previous studies, inconsistencies between registered and published primary outcomes varied between 18% and 49% (14, 19, 20 ) . In our cohort, 24% of the studies that had been registered before study completion showed inconsistencies between the registered and published primary outcomes and/or secondary accuracy outcomes. Performing multiple statistical inferences increases the risk of false-positive findings. The selective reporting of multiple outcomes does not allow the reader of a study to be aware of the magnitude of this risk. In addition, not providing a predefined threshold, but rather estimating one on the basis of the collected data, gives room for manipulation and will usually lead to inflated estimates of test accuracy that are hard to reproduce (21 ) .
To our knowledge, this is the first investigation of failure to publish and selective reporting in such a large and general cohort of test accuracy studies. We are aware of only 1 similar project (11 ) . Brazelli et al. investigated publication rates in a much smaller cohort of conference abstracts of test accuracy studies in stroke research and found that 76% (121 of 160) were subsequently published in full. They did not evaluate discrepancies between protocols and publications (11 ) .
Our results indicate that the problems of failure to publish and selective reporting also appear among test accuracy studies. This would mean that study registration is equally important in this field of research. Although the fact that more and more test accuracy studies are being registered is promising, our results also show that, at this point, study registration for test accuracy studies needs more guidance. The majority of studies are not registered before initiation, registered information varies widely between studies, and essential information (including outcomes) is often registered vaguely or after study completion, if at all. A registration number was provided in slightly more than half of the publications of registered studies, making it difficult to assess whether a study has been previously registered. A reference to a publication was provided in the registry for only one third of published studies, which hampers determination of whether a registered study is published. Many authors also seem to forget to change the status of their study to completed, even among published studies.
Failure to publish and selective reporting among test accuracy studies threaten patient safety because adoption of medical tests into clinical practice on the basis of an incomplete evidence base may lead to inadequate medical decision making (22, 23 ) . Patients may be subjected to the side effects of unnecessary medical interventions on the basis of an erroneous diagnosis or withdraw from an intervention on the basis of an erroneous prognosis. In addition, tests may have potential complications and side effects, and inadequate testing increases pressure on healthcare funds. This is a particular worry in times of economic recession and a continuous increase in healthcare costs. Healthcare policymakers should be able to make an objective appraisal of any given test, on the basis of all the available evidence.
We recommend more research into the extent, drivers, and consequences of failure to publish and selective reporting in test accuracy studies. An obvious next step would be to follow up on a cohort of IRBapproved protocols of test accuracy studies. This way, a more exact estimation of publication rates and a more adequate assessment of discrepancies between the original protocols and the final publications can be made. Above all, we strongly recommend that study registration becomes a requirement for test accuracy studies. However, before implementing such a requirement, guidelines specifically designed for registration of test accuracy studies should be developed. 
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